Table 2:

The CPIC Guidelines for Hydroxychloroquine based on G6PD Phenotype

Predicted G6PD phenotype based on genotypeImplication for phenotypic measuresTherapeutic recommendationClassification of recommendationa
NormalLow-to-no risk of acute hemolytic anemiaNo reason to avoid low-to-no risk drugs based on G6PD statusStrong
DeficientLow-to-no risk of acute hemolytic anemiaNo reason to avoid low-to-no risk drugs based on G6PD status at standard dosesModerate
Deficient with CNSHAHigh risk of acute exacerbation of chronic hemolysisUse all drugs cautiously in this group; if a drug is used, close monitoring for acute exacerbation of chronic hemolysis is recommendedOptional
VariableLow-to-no risk of acute hemolytic anemiaNo reason to avoid low-to-no risk drugs based on G6PD status at standard dosesModerate
IndeterminantUnknown risk of acute hemolytic anemiaTo ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotypeModerate

CNSHA - Chronic non-spherocytic hemolytic anemia, G6PD - glucose-6-phoshate dehydrogenase, CPIC - Clinical Pharmacogenetics Implementation Consortium

a

Rating scheme from (5) Supplement.

From: Hydroxychloroquine Therapy and G6PD Genotype

Cover of Medical Genetics Summaries
Medical Genetics Summaries [Internet].
Pratt VM, Scott SA, Pirmohamed M, et al., editors.
Copyright Notice

All Medical Genetics Summaries content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which permits copying, distribution, and adaptation of the work, provided the original work is properly cited and any changes from the original work are properly indicated. Any altered, transformed, or adapted form of the work may only be distributed under the same or similar license to this one.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.